

CURRICULUM VITAE  
Kent E. Kester, MD, FACP, FIDSA, FASTMH

August 2017

Work Address: Kent E. Kester  
Vice President and Head, Translational Science & Biomarkers  
Sanofi Pasteur, Inc.  
Discovery Drive  
Swiftwater, PA 18370  
Phone: 570-957-1924  
FAX: 570-957-0934  
e-mail: kent.kester@sanofi.com

Current Positions: Vice President and Head, Translational Sciences and Biomarkers, Sanofi Pasteur, Inc.; Attending Physician, Infectious Disease Service, R.A. Cowley Shock Trauma Center, University of Maryland Medical Center, Baltimore, MD; Professor of Medicine, Uniformed Services University School of Medicine, Bethesda, MD

Current duties at Sanofi Pasteur:

Develop clinical/translational strategies and integrated translational plans for all research and early-stage vaccine candidates; lead the internal governance processes involved in the setting and finalization of translational strategies, to include novel antigens, biomarkers, animal models, human challenge studies, and more; identify and operationalize key strategic partnerships for vaccine development, including government, academia, industry, and non-profit organizations; senior direction of Global Clinical Immunology and the VaxDesign site; Sanofi Pasteur representative to the Biovacsafe Consortium; provide direct subject matter expertise support (clinical and translational) to the Sanofi Infectious Disease Therapeutic Strategic Unit

Education: Bucknell University, Lewisburg, PA  
B.S., Biology (1982), *summa cum laude*  
Jefferson Medical College, Philadelphia, PA  
M.D. (1986), *summa cum laude*

Postgraduate Training: University of Maryland Hospital, Baltimore, MD  
Internal Medicine Internship and Residency (1986-89)  
Walter Reed Army Medical Center, Washington, DC  
Infectious Disease Fellowship (1992-95)

Military Training: AMEDD Officer Basic Course (1983)  
Combat Casualty Care Course (1990)  
Medical Management of Chemical Casualties Course (1990)  
AMEDD Officer Advanced Course (1990)  
Advanced Trauma Life Support (ATLS) Course (1990, 2002)  
Medical Defense Against Biological Warfare Course (1991)  
Advanced Trauma Life Support (ATLS) Instructor Course (1991)  
WRAIR Tropical Medicine Course (1994)  
U.S. Army Command and General Staff College (1995)  
Advanced Cardiac Life Support (ACLS) Course (1996)  
Tactical Combat Medical Course (2012)

Positions Held: Staff Internist, Department of Medicine, Brooke Army Medical Center, Ft. Sam Houston, TX (1989-92)  
Infectious Disease Officer and Chief, Serology Section, Department of Immunology, Walter Reed Army Institute of Research, Washington, D.C. (1995-1999)  
Chief, Clinical Vaccine Development Program, Department of Immunology, Walter Reed Army Institute of Research, Washington, DC (1999-2001)  
Chief, Department of Clinical Trials, Walter Reed Army Institute Research, Washington, DC (2001-2004)  
Chief, Infectious Diseases, 249<sup>th</sup> General Hospital, Fort Gordon, GA (PROFIS assignment; 1997-2005)  
Director, Division of Regulated Activities, Walter Reed Army Institute of Research (2004-2006)  
Deputy Commander, Walter Reed Army Institute of Research (2006-2008)  
Commander, Walter Reed Army Institute of Research (2008-2011)  
Associate Dean for Clinical Research, School of Medicine, Uniformed Services University, Bethesda, MD (2011-2014)  
Acting Dean, School of Medicine, Uniformed Services University, Bethesda, MD (October 2013)  
Associate VP and Head, Clinical and Translational Sciences, Sanofi Pasteur, Swiftwater, PA (2014-2015)

Academic Appointments: Clinical Associate, Department of Medicine, University of Maryland School of Medicine, Baltimore, MD (1988-89)  
  
Clinical Instructor, Department of Medicine, University of Texas Health Science Center at San Antonio, San Antonio, TX (1989-90)  
  
Clinical Assistant Professor, Department of Medicine, University of Texas

Health Science Center at San Antonio, San Antonio, TX (1990-92)

Teaching Fellow, Department of Medicine, Uniformed Services  
University of the Health Sciences, Bethesda, MD (1992-93)

Instructor, Department of Medicine, Uniformed Services University of the  
Health Sciences, Bethesda, MD (1993-95)

Assistant Professor, Department of Medicine, Uniformed Services  
University of the Health Sciences, Bethesda, MD (1995-2001)

Associate Professor, Department of Medicine, Uniformed Services  
University of the Health Sciences, Bethesda, MD (2001-2011)

Professor, Department of Medicine, Uniformed Services University of  
the Health Sciences, Bethesda, MD (2011-present)

Clinical Instructor, Department of Medicine, University of Maryland  
School of Medicine, Baltimore, MD (1995-2005)

Clinical Assistant Professor, Department of Medicine, University of  
Maryland School of Medicine, Baltimore, MD (2005-present)

Clinical Assistant Professor, Department of Medicine, Georgetown  
University School of Medicine, Washington, DC (2011-present)

Licensure: Maryland D36095  
Pennsylvania 040278-E

Certifications: Diplomate--National Board of Medical Examiners (1987)  
Diplomate--American Board of Internal Medicine (1989)  
Diplomate--American Board of Internal Medicine/Infectious Diseases  
(1996, 2006, 2016)  
Level III Certified: Science and Technology Management (Defense  
Acquisition University)

Professional Associations: Fellow--American College of Physicians (1995)  
Fellow--Infectious Disease Society of America (2001)  
Fellow--American Society of Tropical Medicine and Hygiene (2012)  
Counselor (2014-2015)  
Member--American Society for Microbiology  
Member--Armed Forces Infectious Disease Society (Councilor 2011-2014)  
Member--Greater Washington Infectious Disease Society

Honors and Awards: Alpha Omega Alpha (1985)  
Hobart Amory Hare Honor Medical Society (1985)  
U. S. Army Health Professions Scholarship (1982-86)  
Finalist--Bailey K. Ashford Research Symposium, WRAMC (1995)  
Order of Military Medical Merit (1998)  
U.S. Army A-Proficiency Designator in Infectious Diseases (2001)  
USUHS James Leonard Award for Excellence  
in Clinical Medicine Teaching (2005 and 2010)  
NASA Ames Honor Award (2010)  
FDA Advisory Committee Service Award (2014)

Military Service: Commissioned 1982, U.S. Army  
Active Duty: 1989-2014  
Final Rank: Colonel

Other Duties: Consultant to the U.S. Army Surgeon General in Medical Research and  
Development (2005-2013)  
Consultant to the U.S. Army Surgeon General in Infectious Diseases  
(2011-2014)  
Member, Anthrax Medical Exemption Policy Working Group, Office of  
The Surgeon General, U.S. Army (2001)  
Member, U.S. Army Surgeon General's Human Subjects  
Research Review Board (HSRRB) (2000-2006)  
Chair, Walter Reed Army Medical Center Institutional Biosafety  
Committee (IBC) (2000-2009); and member, Walter Reed National  
Military Medical Center IBC (2012-2014)  
DoD Representative, U.S. Public Health Service Malaria Diagnostic  
Working Group (2000)  
Army Representative, Federal Malaria Vaccine Coordinating Committee  
(1995-2002)  
Voting Member, U.S. Army Malaria Vaccine Steering Committee  
(1999-2006)  
Member, NIAID/NIH Special Emphasis Panel ZAI1-RCG-M-C2  
Evaluation of Control Measures Against Diseases Other Than  
AIDS (September 2001)  
Member, DMID/NIAID Subcommittee (2009-2014)  
Member, NIAID Advisory Council (2009-2014)  
Member, Scientific Advisory Panel, Africa Malaria Network Trust  
(AMANET) (2001-2003)  
Panel Member, Institute of Medicine, Forum on Microbial Threats  
(2009-2011; 2012-2014)

Panel Member, Health and Security Working Group, Center for Strategic and International Studies (CSIS) (2009)

Panel Member, DoD Working Group on Overseas Health Labs, Center for Strategic and International Studies (CSIS) (2010-2011)

Member, USUHS Infectious Disease Clinical Research Program (IDCRP) Steering Committee (2006-2014; Chair: 2006-2008; 2012-2014)

Panel Member, Future Opportunities in Global Health Research, convened by the Director of the NIH, Bethesda, MD (2010)

Panel Member, Interagency Malaria Symposium (2010)

Panel Member, Joint Infectious Disease Threat Prioritization Panel (2010)

Member, Vaccines and Related Biologics Advisory Committee (VRBPAC), US Food and Drug Administration (2011-2014)

Member, Defense Health Program Joint Program Committee-2 (Infectious Disease Research) (2011-2014)

Member, VA/DoD Medical Research Work Group (2012-2014)

Member, Centers for Disease Control and Prevention Board of Scientific Counselors, Office of Infectious Diseases (2012-2014)

Member, Interagency Advisory Group, The President’s Malaria Initiative (USAID—lead US Government agency) (2012-2014)

Member, DHP RDT&E Research Review Panels (Infectious Disease, Combat Casualty Care, and Neuroscience) (2011-2015)

Member, Joint Warfighter Medical Research Program Review Panel (2014)

Member, Institutional Review Board, Walter Reed Army Institute of Research (2012-present; chair: 2012-2013)

Member, Steering Committee, IMI “Biovacsafe” Consortium (2014-present)

Member, Board of Directors, Medical Technology Enterprise Consortium (<http://www.mtec-sc.org/>; 2015-present)

Member, Presidential Advisory Council on Combating Antibiotic Resistant Bacteria (PACCARB) (2015-present)

Member, Steering Committee, IMI “Periscope” Consortium (2015-present)

Member, Scientific Steering Committee, Human Vaccines Project (<http://humanvaccinesproject.org/>) (2016-present)

Editorial Reviewer for *Journal of Infectious Diseases*, *Clinical Infectious Diseases*, *Proceedings of the National Academy of Sciences USA (PNAS)*, *Scandinavian Journal of Infectious Disease*, *Journal of Infection Control*, *Clinical and Experimental Immunology*, *The American Journal of Tropical Medicine and Hygiene*, *The Journal of Travel Medicine*, and *Vaccine*

## Publications:

1. **Kester KE**. Parenchymal neurocysticercosis. Maryland Medical Journal 1993;42(7):677-679.
2. Byrd JC, Hargis JB, **Kester K**, Hospenthal DR, Weidner S, Diehl L. Fludarabine therapy for lymphoid malignancies is associated with a high number of opportunistic pulmonary infections. Blood 1993;82(10):Supplement 1:138a.
3. Byrd JC, Hargis JB, **Kester K**, Hospenthal DR, Weidner S, Diehl LF. Opportunistic pulmonary infections with fludarabine in previously-treated patients with low-grade lymphoid malignancies: a role for *Pneumocystis carinii* pneumonia prophylaxis. American Journal of Hematology 1995;49:135-142.
4. **Kester KE**, Byrd JC, Rearden TP, Zacher LL, Cragun WH, Hargis JB. A diagnostic dilemma: granulomatous *Pneumocystis carinii* pneumonia in patients with low-grade lymphoid malignancies. Clinical Infectious Diseases 1996;22:1111-1112.
5. Shorr AF, **Kester KE**. Meningitis and hepatitis complicating intravenous immunoglobulin therapy. Annals of Pharmacotherapy 1996;30:1115-1116.
6. Stoute JA, Slaoui M, Heppner DG, Momin P, **Kester KE** et al. A preliminary evaluation of a recombinant circumsporozoite protein vaccine against *Plasmodium falciparum* malaria. New England Journal of Medicine 1997;336:86-91.
7. **Kester KE**, Turiansky GW, McEvoy PL. Nodular, cutaneous microsporidiosis in a patient with AIDS and successful treatment with long-term oral clindamycin. Annals of Internal Medicine 1998;128:911-914.
8. Ockenhouse CF, Sun P, Lanar DE, Welde BT, Hall BT, **Kester K**, Stoute JA, Magill A, Krzych U, et al. Phase I/IIa Safety, immunogenicity, and efficacy trial of NYVAC-Pf7, a pox-vectored, multiantigen, multistage vaccine candidate for *Plasmodium falciparum* malaria. Journal of Infectious Diseases 1998;177:1664-1673.
9. Stoute JA, **Kester KE**, Krzych U, Welde BT, Hall T, et al. Long term efficacy and immune responses following immunization with the RTS,S malaria vaccine. Journal of Infectious Diseases 1998;178:1139-1144.
10. Gozalo A, Lucas C, Cachay M, Welde BT, Hall T, Bell B, Wood J, Watts D, Wooster M, Lyon JA, Moch JK, Haynes JD, Williams JS, Holland C, Watson E, **Kester KE**, Kaslow DC, Ballou WR. Passive transfer of growth-inhibitory antibodies raised against yeast-expressed recombinant Plasmodium falciparum merozoite surface protein-1(19). Am J Trop Med Hyg 1998 Dec;59(6):991-7.

11. Heppner DG Jr, Gasser RA Jr, **Kester KE**. Primaquine prophylaxis against malaria. *Ann Intern Med* 1999 Mar 16;130(6):536-7.
12. Lalvani A, Moris P, Voss G, Pathan AA, **Kester KE**, et al. Potent induction of focused Th1-type cellular and humoral immune responses by RTS,S/SBAS2, a recombinant *Plasmodium falciparum* malaria vaccine. *Journal of Infectious Diseases* 1999;180:1656-64.
13. Doherty TF, Pinder M, Tornieporth N, Carton C, Vigneron L, Milligan P, Ballou WR, Holland CA, **Kester KE**, Voss G, Momin P, Greenwood BM, McAdam KPWJ, Cohen J. A Phase I safety and immunogenicity trial with the candidate malaria vaccine, RTS,S/SBAS2, in semi-immune adults in The Gambia. *American Journal of Tropical Medicine and Hygiene* 1999;61:865-868.
14. Keitel WA, **Kester KE**, Atmar RL, White AC, Bond NH, Holland CA, Krzych U, Palmer DR, Egan A, Diggs C, Ballou WR, Hall BF, Kaslow D. Phase I trial of two recombinant vaccines containing the 19kD carboxy terminal fragment of *Plasmodium falciparum* merozoite surface protein 1 (MSP-1<sub>19</sub>) and T helper epitopes of tetanus toxoid. *Vaccine* 1999;18:531-539.
15. Ballou WR, **Kester KE**, Stoute, JA, Heppner DG. Malaria vaccine: triumphs or tribulations? *Parassitologia* 1999;41:403-408.
16. **Kester KE**, Visvesara GS, McEvoy P. Organism responsible for nodular cutaneous microsporidiosis in a patient with AIDS. *Annals of Internal Medicine* 2000;133:925.
17. **Kester KE**, McKinney DA, Ockenhouse CF, Heppner DG, Hall T, Krzych U, Tornieporth N, Delchambre M, Voss G, Palensky J, Cohen J, Ballou WR. Efficacy of recombinant circumsporozoite protein vaccine regimens against experimental *Plasmodium falciparum* malaria. *Journal of Infectious Diseases* 2001;183:640-647.
18. Forney JR, Magill AJ, Wongsrichanalai C, Sirichaisninthop J, Bautista CT, Heppner DG, Miller RS, Ockenhouse CF, Gubanov A, Shafer R, DeWitt CC, Quino-Ascurra HA, **Kester KE**, Kain KC, Walsh DS, Ballou WR, Gasser RA. Malaria rapid diagnostic devices: performance characteristics of the *ParaSight F* device determined in a multisite field study. *Journal of Clinical Microbiology* 2001;39:2884-2890.
19. Berman JD, Nielsen R, Chulay JD, Dowler M, Kain KC, **Kester KE**, Williams J, Whelen AC, Shmuklarsky MJ. Causal prophylactic efficacy of atovaquone-proguanil (Malarone®) in a human challenge model. *Transactions of the Royal Society of Tropical Medicine and Hygiene* 2001;95:429-432.
20. Bojang KA, Milligan PJM, Pinder M, Vigneron L, Allouche A, **Kester KE**, Ballou WR, Conway DJ, Reece WHH, Gothard P, Yamuah L, Delchambre M, Voss G, Greenwood BM, Hill A, McAdam PWJ, Tornieporth N, Cohen JD, Doherty T. Efficacy of RTS,S/AS02 malaria

vaccine against *Plasmodium falciparum* in semi-immune adult men in The Gambia: a randomised trial. *The Lancet* 2001;358:1927-1934.

21. Heppner DG, Cummings JF, Ockenhouse C, **Kester KE**, Lyon JA, Gordon DM. New World monkey efficacy trials for malaria vaccine development: critical path or detour? *Trends Parasitol* 2001;17:419-425.

22. **Kester KE**. Critical commentary to “Granulomatous *Pneumocystis carinii* pneumonia complicating hematopoietic cell transplantation.” *Pathol Res Pract* 2002;198:559-560.

23. Ballou WR, **Kester KE**, Heppner DG. Pre-erythrocytic malaria vaccines to prevent *Plasmodium falciparum* malaria. *Chem Immunol* 2002;80:253-261.

24. Lee EA, Palmer Dr, Flanagan KL, Reece WH, Odhiambo K, Marsh K, Pinder M, Gravenor MB, Keitel WA, **Kester KE**, Diggs C, Kaslow D, Apostolopoulos V, Ballou WR, Hill AV, Kzyzch U, Plebanski M. Induction of T helper type 1 and 2 responses to 19-kilodalton merozoite surface protein 1 in vaccinated healthy volunteers and adults naturally exposed to malaria. *Infect Immun* 2002;70:117-1421.

25. Angov E, Aufiero BM, Turgeon AM, Van Handenhove M, Ockenhouse CF, **Kester KE**, Walsh DS, McBride JS, Dubois MC, Cohen J, Haynes JD, Eckels KH, Heppner DG, Ballou WR, Diggs CL, Lyon JA. Development and pre-clinical analysis of a *Plasmodium falciparum* Merozoite Surface Protein-1(42) malaria vaccine. *Molecular and Biochemical Parasitology* 2003;128:195-204.

26. McConkey SJ, Reece WHH, Moorthy VS, Webster D, Dunachie S, Butcher G, Vuola JM, Blanchard TJ, Gothard P, Watkins K, Hannan CM, Everaere S, Brown K, **Kester KE**, Cummings J, Williams J, Heppner DG, Pathan A, Flanagan K, Nirmalan A, Roberts MTM, Roy M, Smith GL, Schnieder J, Peto T, Sinden RE, Gilbert SC, Hill AVS. Enhanced T-cell immunogenicity of plasmid DNA vaccines boosted by recombinant modified vaccine virus Ankara in humans. *Nature Medicine* 2003;9:729-735.

27. Schwenk R, Asher LV, Chalom I, Lanar D, Sun P, White K, Keil D, **Kester KE**, Stoute J, Heppner DG, Krzyzch U. Opsonization by antigen-specific antibodies as a mechanism of protective immunity induced by *Plasmodium falciparum* circumsporozoite protein-based vaccine. *Parasite Immunology* 2003;25:17-25.

28. Forney JR, Wongsrichanalai C, Magill AJ, Cragi LG, Sirichaisinthop J, Bautista CT, Miller RS, Ockenhouse CF, **Kester KE**, Aronson NE, Andersen EM, Quino-Ascurra HA, Vidal C, Moran KA, Murray CK, DeWitt CC, Heppner DG, Kain KC, Ballou WR, Gasser RA Jr. Devices for rapid diagnosis of malaria: evaluation of prototype assays that detect *Plasmodium falciparum* histidine-rich protein 2 and a *Plasmodium vivax*-specific antigen. *Journal of Clinical Microbiology* 2003;41:2358-2366.



29. Sun P, Schwenk R, White K, Stoute JA, Cohen J, Ballou WR, Voss G, **Kester KE**, Heppner DG, Krzych U. Protective immunity induced with malaria vaccine, RTS,S, is linked to *plasmodium falciparum* circumsporozoite protein-specific CD4+ and CD8+ T cells producing IFN-gamma. *Journal of Immunology* 2003;171:6961-6967.
30. Reece WH, Pinder M, Gothard PK, Milligan P, Bojang K, Doherty T, Plebanski M, Akinwunmi P, Everaere S, Watkins KR, Voss G, Tornieporth N, Allouche A, Greenwood BM, **Kester KE**, McAdam KP, Cohen J, Hill AV. A CD4(+) T-cell immune response to a conserved epitope in the circumsporozoite protein correlates with protection from natural *Plasmodium falciparum* infection and disease. *Nature Medicine* 2004;10:406-410.
31. Epstein JE, Charoenvit Y, **Kester KE**, Wang R, Newcomer R, Fitzpatrick S, Richie TL, Tornieporth N, Heppner DG, Ockenhouse C, Majam V, Holland C, Abot E, Ganeshan H, Berzins M, Jones T, Freyberg CN, Ng J, Norman J, Carucci DJ, Cohen J, Hoffman SL. Safety, tolerability, and antibody responses in humans after sequential immunization with a PfCSP DNA vaccine followed by the recombinant protein vaccine RTS,S/AS02A. *Vaccine* 2004;22:1592-1603.
32. Wang R, Epstein J, Charoenvit Y, Baraceros FM, Rahardjo N, Gay T, Banania JG, Chattopadhyay R, de la Vega P, Richie TL, Tornieporth N, Doolan DL, **Kester KE**, Heppner DG, Norman J, Carucci DJ, Cohen JD, Hoffman SL. Induction in Humans of CD8+ and CD4+ T cell and antibody responses by sequential immunization with malaria DNA and recombinant protein. *Journal of Immunology* 2004;172:5561-5561.
33. Walsh DS, Pichyangkul S, Gettayacamin M, Tongtawe P, Siegrist CA, Hansukjariya P, **Kester KE**, Holland CA, Voss G, Cohen J, Stewart AV, Miller RS, Ballou WR, Heppner DG Jr. Safety and immunogenicity of rts,s+trap malaria vaccine, formulated in the as02a adjuvant system, in infant rhesus monkeys. *American Journal of Tropical Medicine and Hygiene* 2004;70:499-509.
34. Pichyangkul S, Gettayacamin M, Miller RS, Lyon JA, Angov E, Tongtawe P, Ruble DL, Heppner DG, **Kester KE**, Ballou WR, Diggs CL, Voss G, Cohen JD, Walsh DS. Preclinical evaluation of the malaria candidate *P. falciparum* MSP1 (42) formulated with novel adjuvants or with alum. *Vaccine* 2004;22:3831-3840.
35. Ballou WR, Arevalo-Herrera M, Carucci D, Richie TL, Coarradin G, Diggs C, Druilhe P, Giersing BK, Saul A, Heppner DG, **Kester KE**, Lanar DE, Lyon J, Hill AV, Pan W, Cohen JD. Update on the clinical development of candidate malaria vaccines. *American Journal of Tropical Medicine and Hygiene* 2004;71 (2 Suppl):239-247.
36. Heppner DG Jr, **Kester KE**, Ockenhouse CF, Tornieporth N, Ofori O, Lyon JA, Stewart VA, Dubois P, Lanar DE, Krzych U, Moris P, Angov E, Cummings JF, Leach A, Hall BT, Dutta S, Schwenk R, Hillier C, Barbosa A, Ware LA, Nair L, Darko CA, Withers MR, Ogotu B,

Polhemus ME, Fukuda M, Pichyangkul S, Gettyacamin M, Diggs C, Soisson L, Milman J, Dubois MC, Garçon N, Tucker K, Wittes J, Plowe CV, Thera MA, Duombo OK, Pau MG, Goudsmit J, Ballou WR, Cohen J. Towards an RTS,S-based, multi-stage, multi-antigen vaccine against falciparum malaria: progress at the Walter Reed Army Institute of Research. *Vaccine* 2005;23:2243-2250.

37. Bojang KA, Olodude F, Pinder M, Ofori-Anyinam O, Vigneron L, Fitzpatrick S, Njie F, Kassanga A, Leach A, Milman J, Rabinovich R, McAdam KP, **Kester KE**, Heppner DG, Cohen JD, Tornieporth N, Milligan PJ. Safety and immunogenicity of RTS,S/AS02A candidate malaria vaccine in Gambian children. *Vaccine* 2005;23:4148-4157.

38. Ockenhouse CF, Angov E, **Kester KE**, Diggs C, Soisson L, Cummings JF, Stewart AV, Palmer DR, Mahajan B, Krzych U, Tornieporth N, Delchambre M, Vanhandenhove M, Ofori-Anyinam O, Cohen J, Lyon JA, Heppner DG; the MSP-1 Working Group. Phase I safety and immunogenicity trial of FMP1/AS02A, a *Plasmodium falciparum* MSP-1 asexual blood stage vaccine. *Vaccine* 2006;24:3009-3017.

39. Walsh DS, Gettayacamin M, Leitner WW, Lyon JA, Stewart VA, Marit G, Pichyangkul S, Gosi P, Tongtawe P, **Kester KE**, Holland, CA, Kolodny N, Cohen J, Voss, G, Ballou WR, Heppner, DG. Heterologous prime-boost immunization in rhesus macaques by two, optimally spaced particle-mediated epidermal deliveries of *Plasmodium falciparum*, circumsporozoite protein-encoding DNA, followed by intramuscular RTS,S/AS02A. *Vaccine* 2006;24:4167-4178.

40. Stoute, JA, Heppner DG, Jr., Mason CJ, Siangla J, Opollo MO, **Kester KE**, Vigneron L, Voss G, Walter MJ, Tornieporth N, Cohen JD, Ballou WR. Phase 1 safety and immunogenicity trial of malaria vaccine RTS,S/AS02A in adults in a hyperendemic region of western Kenya. *American Journal of Tropical Medicine and Hygiene* 2006;75(1):166-170.

41. Stewart VA, McGrath SM, Walsh DS, Davis S, Hess AS, Ware LA, **Kester KE**, Cummings JF, Burge JR, Voss G, Delchambre M, Garçon N, Tang DB, Cohen JD, Heppner DG. Pre-clinical evaluation of new adjuvant formulations to improve the immunogenicity of the malaria vaccine RTS,S/AS02A. *Vaccine* 2006;24(42-43): 6483-6492.

42. Stewart VA, Walsh DS, McGrath SM, **Kester KE**, Cummings JF, Voss G, Delchambre M, Garçon N, Cohen JD, Heppner DG. Cutaneous delayed-type hypersensitivity (DTH) in a multi-formulation comparator trial of the anti-falciparum malaria vaccine candidate RTS,S in rhesus macaques. *Vaccine* 2006;24(42-43): 6493-64502.

43. Ockenhouse CF, Hu WC, **Kester KE**, Cummings JF, Stewart A, Heppner DG, Jedlicka AE, Scott AL, Wolfe ND, Vahey M, Burke DS. Common and divergent immune response signaling pathways discovered in peripheral blood mononuclear cell gene expression patterns in presymptomatic and clinically apparent malaria. *Infection and Immunity* 2006;74(10): 5561-5573.

44. Stoute JA, Gombe J, Withers MR, Siangla J, McKinney D, Onyango M, Cummings JF, Milman J, Tucker K, Soisson L, Stewart VA, Lyon JA, Angov E, Leach A, Cohen J, **Kester KE**, Ockenhouse CF, Holland CA, Diggs CL, Wittes J, Heppner DG Jr; MSP-1 Malaria Vaccine Working Group. Phase 1 randomized double-blind safety and immunogenicity trial of Plasmodium falciparum malaria merozoite surface protein FMP1 vaccine, adjuvanted with AS02A, in adults in western Kenya. *Vaccine* 2007;25(1): 176-184.
45. Polhemus ME, Magill AJ, Cummings JF, **Kester KE**, Ockenhouse CF, Lanar DE, Dutta S, Barbosa A, Soisson L, Diggs CL, Robinson SA, Haynes JD, Stewart VA, Ware LA, Brando C, Krzych U, Bowden RA, Cohen JD, Dubois MC, Ofori-Anyinam O, De-Kock E, Ballou WR, Heppner DG. Phase I dose escalation safety and immunogenicity trial of Plasmodium falciparum apical membrane protein (AMA-1) FMP2.1, adjuvanted with AS02A, in malaria-naïve adults at the Walter Reed Army Institute of Research. *Vaccine* 2007;25(21): 4203-4212.
46. **Kester KE**, McKinney DA, Tornieporth N, Ockenhouse CF, Heppner DG, Hall T, Welde BT, White K, Sun P, Schwenk R, Krzych U, Delchambre M, Voss G, Dubois MC, Gasser RA, Dowler MG, O'Brien M, Wittes J, Wirtz R, Cohen J, Ballou WR, RTS,S Malaria Vaccine Evaluation Group. A phase I/IIa safety, immunogenicity, and efficacy bridging randomized study of a two-dose regimen of liquid and lyophilized formulations of the candidate malaria vaccine RTS,S/AS02A in malaria-naïve adults. *Vaccine* 2007;25(29): 5359-5366.
47. **Kester KE**, Cummings JF, Ockenhouse CF, Nielsen R, Hall, BT, Gordon DM, Schwenk RJ, Krzych U, Holland CA, Richmond G, Dowler MG, Williams J, Wirtz RA, Tornieporth N, Vigneron L, Delchambre M, Demoitie M-A, Ballou WR, Cohen J, Heppner DG, RTS,S Evaluation Group. Phase 2a trial of 0, 1, 3 month and 0, 7, 28 day immunization schedules of malaria vaccine RTS,S/AS02 in malaria-naïve adults at the Walter Reed Army Institute of Research. *Vaccine* 2008;26(18): 2191-2202.
48. Shott JP, McGrath SM, Pau MG, Custers JH, Ophorst O, Demoitie MA, Dubois MC, Komisar J, Cobb M, **Kester KE**, Dubois P, Cohen J, Goudsmit J, Heppner DG, Stewart VA. Adenovirus 5 and 35 vectors expressing Plasmodium falciparum circumsporozoite surface protein elicit potent antigen-specific cellular IFN-gamma and antibody responses in mice. *Vaccine* 2008;26(23): 2818-2823.
49. Bojang K, Milligan P, Pinder M, Doherty T, Leach A, Ofori-Anyinam O, Lievens M, **Kester K**, Schaecher K, Ballou WR, Cohen J. Five-year safety and immunogenicity of GlaxoSmithKline's candidate malaria vaccine RTS,S/AS02 following administration to semi-immune adult men living in a malaria-endemic region of The Gambia. *Human Vaccines* 2009;5(4): 242-247.
50. Spring MD, Cummings JF, Ockenhouse CF, Dutta S, Reidler R, Angov E, Bergmann-Leitner E, Stewart VA, Bittner S, Juompan L, Kortepeter MG, Nielsen R, Tierney E, Ware LA, Dowler M, Hermsen CC, Sauerwein RW, de Vlas SJ, Ofori-Anyinam O, Lanar DE, Williams JL, **Kester**

**KE**, Tucker K, Shi M, Malkin E, Long C, Diggs CL, Soisson L, Dubois MC, Ballou WR, Cohen J, Heppner DG Jr. Phase 1/2a study of the malaria vaccine candidate apical membrane antigen-1 (AMA-1) administered in adjuvant system AS01B or AS02A. *PLoS One* 2009;4(4): e5254.

51. **Kester KE**, Cummings JF, Ofori-Anyinam O, Ockenhouse CF, Krzych U, Moris P, Schwenk R, Nielsen RA, Debebe Z, Pinelis E, Juompan L, Williams J, Dowler M, Stewart VA, Wirtz RA, Dubois M-C, Lievens M, Cohen J, Ballou WR, Heppner DG, RTS,S Vaccine Evaluation Group. Randomized, double-blind, phase 2a trial of Falciparum malaria vaccines RTS,S/AS01B and RTS,S/AS02A in malaria-naïve adults; safety, efficacy, and immunologic associates of protection. *Journal of Infectious Diseases* 2009;200:337-346.

52. Polhemus ME, Remich SA, Ogutu BR, Waitumbi JN, Otieno L, Apollo S, Cummings JF, **Kester KE**, Ockenhouse CF, Stewart A, Ofori-Anyinam O, Ramboer I, Cahill CP, Lievens M, Dubois MC, Demoitie MA, Leach A, Cohen J, Ballou WR, Heppner DG Jr. Evaluation of RTS,S/AS02A and RTS,S/AS01B in adults in a high malaria transmission area. *PLoS One* 2009;4(7): e66465.

53. Vahey MT, Wang Z, **Kester KE**, Cummings J, Heppner DG Jr., Nau ME, Ofori-Anyinam O, Cohen J, Coche T, Ballou WR, Ockenhouse CF. Expression of genes associated with immunoproteasome processing of major histocompatibility complex peptides is indicative of protection with adjuvanted RTS,S malaria vaccine. *Journal of Infectious Diseases* 2010;201(4):580-589.

54. Cummings JF, Spring MD, Schwenk RJ, Ockenhouse CF, **Kester KE**, Polhemus ME, Walsh DS, Yoon In-Kyu, Propseri C, Juompan LY, Lanara DE, Krzych U, Hall BT, Ware LA, Stewart VA, Williams J, Dowler M, Nielsen RK, Hillier CJ, Giersing BK, Dubovsky F, Malkin E, Tucker K, Dubois M-C, Cohen JD, Ballou WR, Heppner DG, Jr. Recombinant Liver Stage Antigen-1 (LSA-1) formulated with AS01 or AS02 is safe, elicits high titer antibody and induces IFN- $\gamma$ /IL-2 CD4<sup>+</sup> T cells but does not protect against experimental *Plasmodium falciparum* infection. *Vaccine* 2010;28: 5135-5144.

55. Lesho E, Craft D, Kirkup BC Jr, Waterman P, Summers A, Vahey MT, **Kester KE**, Bowden R. Surveillance, characterization, and preservation of multidrug-resistant bacteria. *Lancet Infectious Diseases* 2011;11(1); 8-10.

56. Lumsden JM, Schwenk RJ, Rein LE, Moris P, Janssens M, Ofori-Anyinam O, Cohen J, **Kester KE**, Heppner DG, Krzych U. Protective immunity induced with the RTS,S/AS vaccine is associated with IL-2 and TNF- $\alpha$  producing effector and central memory CD4<sup>+</sup> T cells. *PLoS One* 2011;6(7): e20775.

57. Schwenk R, Lumsden JM, Rein LE, Juompan L, **Kester KE**, Heppner DG, Krzych U. Immunization with the RTS,S/AS malaria vaccine induces IFN- $\gamma$ <sup>+</sup> CD4 T cells that recognize

only discrete regions of the circumsporozoite protein and these specificities are maintained following booster immunizations and challenge. *Vaccine* 2011;29:8847-8854.

58. Hospenthal DR, Murray CK, Andersen RC, Bell RB, Calhoun JH, Cancio LC, Cho JM, Chung KK, Clasper JC, Colyer MH, Conger NG, Costanzo GP, Crouch HK, Curry TK, D'Avignon LC, Dorlac WC, Dunne JR, Eastridge BJ, Ficke JR, Fleming ME, Forgione MA, Green AD, Hale RG, Hayes DK, Holcomb JB, **Kester KE**, Martin GJ, Moores LE, Obremsky WT, Petersen K, Renz EM, Saffle JR, Solomkin JS, Sutter DE, Tribble DR, Wenke JC, Whitman TJ, Wiesen AR, Wortmann GW; Infectious Diseases Society of America; Surgical Infection Society. Executive summary: Guidelines for the prevention of infections associated with combat-related injuries: 2011 update: endorsed by the Infectious Diseases Society of America and the Surgical Infection Society. *Journal of Trauma* 2011;71 (2 Suppl 2):S202-209.

59. Hospenthal DR, Murray CK, Andersen RC, Bell RB, Calhoun JH, Cancio LC, Cho JM, Chung KK, Clasper JC, Colyer MH, Conger NG, Costanzo GP, Crouch HK, Curry TK, D'Avignon LC, Dorlac WC, Dunne JR, Eastridge BJ, Ficke JR, Fleming ME, Forgione MA, Green AD, Hale RG, Hayes DK, Holcomb JB, **Kester KE**, Martin GJ, Moores LE, Obremsky WT, Petersen K, Renz EM, Saffle JR, Solomkin JS, Sutter DE, Tribble DR, Wenke JC, Whitman TJ, Wiesen AR, Wortmann GW; Infectious Diseases Society of America; Surgical Infection Society. Guidelines for the prevention of infections associated with combat-related injuries: 2011 update: endorsed by the Infectious Diseases Society of America and the Surgical Infection Society. *Journal of Trauma* 2011;71 (2 Suppl 2): S210-234.

60. Antonic V, Stojadinovic A, **Kester KE**, Weina PJ, Brücher BL, Protic M, Avital I, Izadjoo M. Significance of infectious agents in colorectal cancer development. *Journal of Cancer* 2013;4(3):227-40.

61. White MT, Bejon P, Olotu A, Griffin JT, Riley EM, **Kester KE**, Ockenhouse CF, Ghani AC. The relationship between RTS,S vaccine-induced antibodies, CD4<sup>+</sup> T cell responses and protection against *Plasmodium falciparum* infection. *PLoS One*. 2013 Apr 16;8(4):e61395.

62. Lesho EP, Waterman PE, Chukwuma U, McAuliffe K, Neumann C, Julius MD, Crouch H, Chandrasekera R, English JF, Clifford RJ, **Kester KE**. The Antimicrobial Resistance Monitoring and Research (ARMoR) Program: the Department of Defense's Response to Escalating Antimicrobial Resistance. *Clin Infect Dis*. 2014;59:390-397.

63. **Kester KE**, Heppner DG, Moris P, Ofori-Anyinam O, Krzych U, Tornieporth N, McKinney D, Delchambre M, Ockenhouse CF, Voss G, Holland C, Beckey JP, Ballou WR, Cohen J, RTS,S/TRAP Group. Sequential Phase 1 and Phase 2 randomized, controlled trials of the safety, immunogenicity and efficacy of combined pre-erythrocytic vaccine antigens RTS,S and TRAP formulated with AS02 Adjuvant System in healthy, malaria naïve adults. *Vaccine* 2014;32:6683-6691.

64. van den Berg RA, Coccia M, Ballou WR, **Kester KE**, Ockenhouse CF, Vekemans J, Jongert E, Didierlaurent AM, van der Most RG. Predicting RTS,S vaccine-mediated protection from transcriptomes in a malaria-challenge clinical trial. *Frontiers in Immunology* 2017;8:557.

### **Book Chapters:**

1. **Kester KE**. Toxoplasmosis. In: Kelley PW, ed. *Military Preventive Medicine: Mobilization and Deployment*. In: Zajtchuk R, Bellamy RF eds. *The Textbook of Military Medicine*. Washington, DC: The Borden Institute and the Office of the Surgeon General, U.S. Army (2002).

2. Moran KA, **Kester KE**. Malaria Vaccines. In Schlagenhauf P, ed. *Travelers' Malaria*. Decker; (2001).

3. Polhemus ME, **Kester KE**, Infections. In Tsokos GC and Atkins JL, eds. *Combat Medicine*. Humana (2003).

4. Heppner DG, Jr., Cummings JF, Ockenhouse CF, **Kester KE**, Cohen JD, Ballou WR. Adjuvanted RTS,S and other protein-based pre-erythrocytic stage malaria vaccines. In Levine MM, Kaper JB, Rappuoli R, Liu MA, Good MF, eds. *New Generation Vaccines*. Marcel Dekker (2004).

5. Heppner DG, Jr., Moran KA, **Kester KE**, Cummings JF. Prospects for a Travelers' Malaria Vaccine. In Schlagenhauf-Lawlor P, ed. *Travelers' Malaria*. Decker (2008).

6. **Kester KE**, Rice CL. Bridging science and practice—a case study: the military translation of innovative responses to urgent military medical needs into widespread clinical practice. In Wartman SA, ed. *The Transformation of Academic Health Centers*. Elsevier (2015).

### **Selected Abstracts and Other Presentations:**

1. Byrd JC, Hargis JB, **Kester K**, Hospenthal D, Weidner S, Diehl L. Fludarabine therapy is associated with a high number of opportunistic pulmonary infections. Army Regional ACP Meeting, Orlando, FL, 18-21 November 1993.

2. **Kester KE**, Byrd JC, Rearden TP, Zacher LL, Cragun WH, Hargis JB. Granulomatous *Pneumocystis carinii* pneumonia (PCP) complicating low-grade lymphoid malignancies. General Meeting of the American Society for Microbiology, Washington, DC, 21-25 May 1995.

3. Magill AJ, Fries BT, Gordon DM, Welde BT, Owens R, Krzych U, Schneider IP, Wirtz RA, **Kester K**, Ockenhouse CF, Stoute JA, Ballou WR. Protective efficacy of a liposome encapsulated R32NS1 *Plasmodium falciparum* malaria vaccine in a human challenge model. 44th Annual Meeting of the American Society of Tropical Medicine and Hygiene, San Antonio, TX, 17-21 November 1995.

4. Glenn GM, **Kester K**, Magill A, Alving CR, Richards RL, Ballou WR. IgG1 subclass antibodies correlate with protection in liposomal R32NS1 malaria vaccine challenge trial. Third Annual IBC Vaccine Conference, Rockville, MD, March 1996.
5. Keitel W, **Kester K**, Atmar R, White AC, Diggs C, Ballou WR, Kaslow D. Safety and immunogenicity of two recombinant vaccines based upon *Plasmodium falciparum* Merozoite Surface Protein 1 (P30P2 MSP-1<sub>19</sub>). 35th Annual Meeting of the Infectious Diseases Society of America, San Francisco, CA, 13-16 September 1997.
6. Heppner DG, Ngampochjana M, Tongtawe P, Stoute J, **Kester K**, et al. Use of a rhesus model to optimize formulations and dosing regimens of the candidate Falciparum malaria vaccine, RTS,S. 45th Annual Meeting of the American Society of Tropical Medicine and Hygiene, Baltimore, MD, December 1-5, 1996.
7. Stoute JA, Heppner DG, Schwenk R, **Kester K**, et al. Safety, immunogenicity and efficacy of a *Plasmodium falciparum* circumsporozoite protein-hepatitis B surface antigen subunit vaccine (RTS,S). 45th Annual Meeting of the American Society of Tropical Medicine and Hygiene, Baltimore, MD, December 1-5, 1996.
8. Krzych U, Schwenk R, White KL, Malik A, Sun P, Kolodny N, Lalvani A, Hill AV, Stoute JA, **Kester KE**, et al. Evaluation of cellular responses induced by recombinant *Plasmodium falciparum* circumsporozoite protein RTS,S vaccine. 46th Annual Meeting of the American Society of Tropical Medicine and Hygiene, Orlando, FL, December 7-11, 1997.
9. Holland, CA, Glenn GM, Williams J, Watson E, Ballou WR, **Kester KE**. Design and analysis of a quantitative IgG subclass ELISA for use in malaria vaccine studies. 46th Annual Meeting of the American Society of Tropical Medicine and Hygiene, Orlando, FL, December 7-11, 1997.
10. Sun P, Schwenk R, White KL, Lalvani A, Hill AV, Kolodny N, Stoute JA, **Kester KE**, et al. Mapping of fine antigen specificities of IFN-gamma-producing T lymphocytes induced by recombinant *Plasmodium falciparum* circumsporozoite protein RTS,S vaccine. 46th Annual Meeting of the American Society of Tropical Medicine and Hygiene, Orlando, FL, December 7-11, 1997.
11. Lanar DE, Abbott MR, DeArmas VM, Miller VL, Stoute JA, **Kester KE**, et al. High level expression, purification and immunological analysis of *Plasmodium falciparum* CS protein. 46th Annual Meeting of the American Society of Tropical Medicine and Hygiene, Orlando, FL, December 7-11, 1997.
12. Rossi CA, Lewis TE, Mihalic KA, Moss DW, Watts DM, Lucas CM, **Kester K**, Henchal EA. Malaria: A cause for false-positive reactions in IgM capture ELISAS. 46th Annual Meeting of the American Society of Tropical Medicine and Hygiene, Orlando, FL, December 7-11, 1997.

13. **Kester KE**. Malaria vaccine development. First International Military Healthcare Symposium, Caracas, Venezuela, June 1998 (invited speaker).
14. Heppner DG, Gettayacamin M, Slaoui M, Voss G, Garcon N, Momin P, Tongtawe P, Pichyangkul S, Walsh DS, **Kester K**, Holland C, Watson E, Wirtz RA, Parrish J, Ballou WR, Cohen J. Use of a Rhesus model to optimize formulations of the candidate falciparum malaria vaccine antigens RTS,S and TRAP. 47th Annual Meeting of the American Society of Tropical Medicine and Hygiene, San Juan, PR, October 18-22, 1998.
15. Walsh DS, Gettayacamin M, Lyon JA, Saengkrai P, Tongtawe P, Pichyangkul S, **Kester K**, Holland C, Watson E, Parrish J, Wirtz R, Cohen J, Momin P, Voss G, Heppner DG, Ballou WR. Prime-boost immunization with epidermal falciparum CSP-based DNA and recombinant CSP (RTS,S) in rhesus malaria vaccine model. 47th Annual Meeting of the American Society of Tropical Medicine and Hygiene, San Juan, PR, October 18-22, 1998.
16. **Kester KE**, Stoute JA, Welde BT, Ockenhouse CF, Voss G, Hall T, Van Handenhove M, Van der Heyden B, Golenda C, Momin P, Krzych U, Glenn GM, Delchambre M, Tornieporth N, Poley GE, Montemarano A, Le T, Holland CA, Gordon DM, Cohen J, Ballou WR. Dosage and schedule optimization of the *Plasmodium falciparum* circumsporozoite-hepatitis B surface antigen subunit vaccine RTS,S. 47th Annual Meeting of the American Society of Tropical Medicine and Hygiene, San Juan, PR, October 18-22, 1998.
17. Doherty T, Pinder M, Tornieporth N, Carton C, Vigneron L, Reece W, Hill A, Lebanksi M, Flanagan K, Akinwunmi P, Ballou WR, **Kester KE**, Holland CA, Voss G, Momin P, McAdam K, Cohen J. Safety and immunogenicity of the RTS,S malaria vaccine (SmithKline Beecham Biologicals) in semi-immune African men in The Gambia. 47th Annual Meeting of the American Society of Tropical Medicine and Hygiene, San Juan, PR, October 18-22, 1998.
18. Stewart VA, Weiss WR, de Taisne C, Tine JA, Abbott MR, DeArmas VM, Miller VM, **Kester KE**, Holland CA, Hoffman SL, Ballou WR, Lanar DE. Comparison between antibody responses induced by DNA and NYVAC-Pf7 malaria vaccine candidates after boosting with recombinant proteins. 47th Annual Meeting of the American Society of Tropical Medicine and Hygiene, San Juan, PR, October 18-22, 1998.
19. **Kester KE**. Malaria vaccine development. Army Regional ACP Meeting, Reston, VA, November 18-21, 1998 (invited speaker).
20. **Kester KE**, Ockenhouse CF, Heppner DG, McKinney D, Welde BT, Hall T, Stoute JA, Voss G, Van Handenhove M, Van der Heyden B, Golenda C, Dowler M, Momin P, Krzych U, Delchambre M, Tornieporth N, Gordon DM, Cohen J, Ballou WR. Schedule optimization of the *Plasmodium falciparum* circumsporozoite-hepatitis B surface antigen subunit vaccine RTS,S/SBAS2. MIM African Malaria Conference, Durban, South Africa, March 14-19 1999.



21. Stoute JA, Mason C, Siangla J, Opollo M, Vigneron L, **Kester KE**, Heppner DG, Tornieporth N, Voss G, Ballou WR, Cohen J. Safety and immunogenicity of the lyophilized RTS,S/SBAS2 malaria vaccine in a malaria-experienced adult population of western Kenya. MIM African Malaria Conference, Durban, South Africa, March 14-19 1999.
22. Doherty T, Pinder M, Tornieporth N, Carton C, Vigneron L, Ballou WR, **Kester KE**, Holland CA, Voss G, Momin P, Greenwood B, McAdam KPWJ, Cohen J. The RTS,S/SBAS2 malaria vaccine (SmithKline Beecham Biologicals): safety and immunogenicity in semi-immune African men in The Gambia. MIM African Malaria Conference, Durban, South Africa, March 14-19 1999.
23. Schwenk R, **Kester K**, Asher L, Voss G, Cohen J, Ballou WR, Krzych U. CS protein-specific opsonizing antibodies induced by the RTS,S malaria mediate protection. 48th Annual Meeting of the American Society of Tropical Medicine and Hygiene, Washington, DC, November 28-December 2, 1999.
24. Stewart VA, Weiss WR, de Taisne C, Tine J, Abbott MR, DeArmas VM, Miller VL, **Kester KE**, Holland CA, Hoffman SL, Aguiar J, Ballou WR, Lanar DE. Multivariant antibody responses to multiantigen malaria vaccine candidates in rhesus monkeys (*M. mulatta*). 48th Annual Meeting of the American Society of Tropical Medicine and Hygiene, Washington, DC, November 28-December 2, 1999.
25. Holland CA, Williams J, Momin P, Delchambre M, Dubois MC, Watson E, Mowery K, Tornieporth N, Vigneron L, Voss, G, Cohen J, Ballou WR, **Kester KE**. Humoral immune responses in recipients of two formulations of the candidate malaria vaccine RTS,S/SBAS2. 48th Annual Meeting of the American Society of Tropical Medicine and Hygiene, Washington, DC, November 28-December 2, 1999.
26. Bojang KA, Doherty T, Pinder M, Yamuah L, Vigneron L, Delchambre M, Voss G, Ballou WR, **Kester K**, Cohen J, Greenwood BM, Hill AVS, McAdam KPWJ, Tornieporth N. Safety and immunogenicity of the RTS,S/SBAS2 malaria vaccine in malaria-experienced Gambian men. 48th Annual Meeting of the American Society of Tropical Medicine and Hygiene, Washington, DC, November 28-December 2, 1999.
27. Sun PF, Schwenk R, Palmer D, Berenzon D, Stoute JA, **Kester KE**, Cohen J, Voss G, Ballou WR, Heppner DG, Krzych U. T lymphocyte responses induced by immunization with the candidate *Plasmodium falciparum* vaccine RTS,S/SBAS2. 49<sup>th</sup> Annual Meeting of the American Society of Tropical Medicine and Hygiene, Houston, TX, October 29-November 2, 2000.
28. **Kester KE**, Heppner DG, Ockenhouse CF, Hall BT, Voss G, De Buyl E, Van Handenhove M, Gordon DM, Krzych U, Dubois M-C, Delchambre M, Tornieporth N, Vigneron L, Ballou WR, Cohen J. Double-blind, randomized Phase I/IIa trial of SmithKline Beecham's candidate

malaria vaccine RTS,S+TRAP/SBAS2 and TRAP/SBAS2. 49<sup>th</sup> Annual Meeting of the American Society of Tropical Medicine and Hygiene, Houston, TX, October 29-November 2, 2000.

29. Cummings JF, Stoute JA, Heppner DG, **Kester KE**, Gasser RA, Moran K, Shanks GD, Mason C, Prescott WR, Tang D, Martin L. A critical evaluation of exclusion/inclusion criteria for a randomized, double-blind, placebo controlled evaluation of weekly tafenoquine (WR 238605/SB 252263) compared to mefloquine for chemosuppression of *Plasmodium falciparum* in western Kenya. 49<sup>th</sup> Annual Meeting of the American Society of Tropical Medicine and Hygiene, Houston, TX, October 29-November 2, 2000.

30. **Kester KE**, Stoute JA, Mason C, Siangla J, Opollo M, Vigneron L, Walter M, Heppner DG, Tornieporth N, Voss G, Ballou WR, Cohen J. Safety and immunogenicity of the lyophilized RTS,S/SBAS2 malaria vaccine in a malaria-experienced adult population of western Kenya. 49<sup>th</sup> Annual Meeting of the American Society of Tropical Medicine and Hygiene, Houston, TX, October 29-November 2, 2000.

31. Holland CA, Williams J, Delchambre M, Watson E, Mowery K, Tornieporth N, Vigneron L, Voss G, Cohen J, Ballou WR, Heppner DG, **Kester KE**. Humoral immune responses in recipients of two candidate malaria vaccines RTS,S+TRAP/SBAS2 and TRAP/SBAS2. 49<sup>th</sup> Annual Meeting of the American Society of Tropical Medicine and Hygiene, Houston, TX, October 29-November 2, 2000.

32. Pichyangkul S, Miller RS, Tongtawe P, Gettayacamin M, Colgin L, Ruble D, Heppner DG, **Kester KE**, Lyon J, Angov E, Ockenhouse CF, Ballou WR, Diggs CL, Voss G, Cohen J, Walsh DS. Comparative immunogenicity of the malaria vaccine candidate MSP-1<sub>42</sub> formulated in SBAS2 or aluminum hydroxide in rhesus monkeys. 49<sup>th</sup> Annual Meeting of the American Society of Tropical Medicine and Hygiene, Houston, TX, October 29-November 2, 2000.

33. Kurtis JD, Holland C, Grimes JM, Lanar DE, Mtalib R, **Kester K**, Duffy PE. IgM Anti-LSA-1 antibodies predict resistance to infection with *Plasmodium falciparum* in a holoendemic area of western Kenya. 50<sup>th</sup> Annual Meeting of the American Society of Tropical Medicine and Hygiene, Atlanta, GA, November 11-15, 2001.

34. Holland CA, Williams J, Heppner DG, Tornieporth N, Vigneron L, Delchambre M, Cohen J, **Kester KE**. Humoral immune responses in recipients of RTS,S/AS02 when given in two short course schedules. 50<sup>th</sup> Annual Meeting of the American Society of Tropical Medicine and Hygiene, Atlanta, GA, November 11-15, 2001.

35. McGrath SM, Davis SA, Manganello LM, **Kester KE**, Voss G, Cohen J, Heppner DG, Stewart VA. Use of the Elispot assay in rhesus macaques for optimization of the RTS,S malaria vaccine candidate with new adjuvant formulations. 50<sup>th</sup> Annual Meeting of the American Society of Tropical Medicine and Hygiene, Atlanta, GA, November 11-15, 2001.

36. **Kester KE**, Cummings JF, Ockenhouse CF, Hall BT, Gordon DM, Krzych U, Holland CA, Tornieporth N, Vigneron L, Delchambre M, Cohen J, Heppner DG. Safety, immunogenicity, and preliminary efficacy of two short course schedules of GlaxoSmithKline's candidate malaria vaccine RTS,S/AS02. 50<sup>th</sup> Annual Meeting of the American Society of Tropical Medicine and Hygiene, Atlanta, GA, November 11-15, 2001.
37. Stewart VA, McGrath SM, Davis SA, Manganello LM, **Kester KE**, Cohen J, Voss G, Heppner DG. Comparison of three novel adjuvants and an accelerated administration schedule in rhesus macaques for optimization of the RTS,S anti-falciparum malaria candidate vaccine. 50<sup>th</sup> Annual Meeting of the American Society of Tropical Medicine and Hygiene, Atlanta, GA, November 11-15, 2001.
38. Ockenhouse CF, Angov E, **Kester KE**, Palmer D, Nesterova G, Diggs C, Cummings J, Haynes JD, Mahajan B, Krzych U, Tornieporth N, Delchambre M, Vanhandenhove M, Heppner DG, Cohen J, Lyon JA. Phase I safety and immunogenicity trial of FMP1/AS02A, a *Plasmodium falciparum* MSP1 asexual stage vaccine. 51<sup>st</sup> Annual Meeting of the American Society of Tropical Medicine and Hygiene, Denver, CO, November 10-14, 2002.
39. Withers MR, Stoute JA, Gombe JA, Wasunna KM, Cummings J, Ohas E, **Kester KE**, McKinney DE, Onyango M, Milman J, Ockenhouse C, Tucker K, Angov E, Diggs C, Heppner DG, Leach A, Holland C, Cohen J, Tornieporth N, Lyon J. Double-blind randomized safety and immunogenicity trial of *Plasmodium falciparum* MSP-1 (42) adjuvanted in AS02A vs. rabies in malaria-experience adults in western Kenya. 51<sup>st</sup> Annual Meeting of the American Society of Tropical Medicine and Hygiene, Denver, CO, November 10-14, 2002.
40. Cummings JF, Polhemus ME, **Kester KE**, Ockenhouse CF, Gasser RA Jr., Magill AJ, Coyne P, Wortmann G, Oster CN, Nielsen RK, Schaecher K, Holland CA, Gordon D, Lyon J, Angov E, Hall T, Diggs C, Cohen J, Tornieporth N, Delchambre M, Dubois MC, Vigneron L, Soisson L, Wittes J, Heppner DG. Safety, immunogenicity, and efficacy of candidate malaria vaccine containing CSP and MSP-1 antigens. 51<sup>st</sup> Annual Meeting of the American Society of Tropical Medicine and Hygiene, Denver, CO, November 10-14, 2002.
41. Ockenhouse CF, **Kester KE**, Cummings J, Stewart A, Nau M, Vahey M. Signature patterns of global gene expression in human malaria infection using high-density oligonucleotide microarrays. 51<sup>st</sup> Annual Meeting of the American Society of Tropical Medicine and Hygiene, Denver, CO, November 10-14, 2002.
42. Polhemus ME, Magill A, Cummings JF, **Kester K**, Ockenhouse C, Soisson L, Diggs C, Robinson S, Stewart A, Haynes JD, Dutta S, Krzych U, Ballou WR, Cohen J, Anyinam O, Heppner DG. Phase 1 dose escalation study of malaria blood stage vaccine based upon recombinant apical merozoite antigen-1 (AMA-1) formulated with GSK Biological's adjuvant AS02A. 53<sup>rd</sup> Annual Meeting of the American Society of Tropical Medicine and Hygiene, Miami Beach, FL. November 7-11, 2004.

43. **Kester KE**. MAL-027: A Phase I/IIa Trial of RTS,S/AS01B vs. RTS,S/AS02A in Adults at the Walter Reed Army Institute of Research. 54<sup>th</sup> Annual Meeting of the American Society of Tropical Medicine and Hygiene, Washington, DC, December 11-15, 2005.

44. McGrath S, Cummings J, Kortepeter M, Nielsen R, Tierney E, Ofori-Anyinam O, Dutta S, Lanar D, Sedegah M, **Kester K**, Malkin E, Diggs C, Soisson L, Dubois M-C, Ballou R, Cohen J, Krzych U, Ockenhouse C, Heppner G, Spring M. Multi-functional T-cell responses induced by the AS01 or AS02 adjuvanted malaria vaccine candidate apical membrane antigen-1 (AMA-1) administered to malaria-naïve adults. 57<sup>th</sup> Annual Meeting of the American Society of Tropical Medicine and Hygiene, New Orleans, LA, December 7-11 2008.

45. Lumsden J, Schwenk RJ, Egner L, Cohen J, Ballou R, Ofori-Anyinam O, Moris P, **Kester KE**, Heppner DG, Krzych U. IL-2-producing effector memory and central memory CD4+ T cell subsets are associated with protective immunity in RTS,S-immunized subjects. 58<sup>th</sup> Annual Meeting of the American Society of Tropical Medicine and Hygiene, Washington, DC, November 18-22, 2009.

46. **Kester KE**. Military development of sites for vaccine and drug trials. 48<sup>th</sup> Annual Meeting of the Infectious Disease Society of America, Vancouver, BC, October 21-24, 2010 (Invited Speaker).

#### **Selected Other Presentations**

1. First International Venezuelan Military Healthcare Symposium. Caracas, Venezuela, Spring 1998 (“Malaria Vaccine Development” and “Meningitis”). [Invited Speaker]

2. Army Regional ACP Meeting. Reston, VA 18-21 November 1998 (“Malaria Vaccine Development”). [Invited Speaker]

3. Malaria in Africa Meeting/Multilateral Initiative Against Malaria, Durban, South Africa, 14-18 March 1999 (“Schedule Optimization of the Candidate Malaria Vaccine RTS,S”). [Invited Speaker]

4. Molecular Approaches to Malaria, Lorne, Australia, 2-5 February 2000 (“Double-Blind, Randomized, Phase I/IIa Trial of SmithKline Beecham’s Candidate Malaria Vaccines RTS,S+TRAP and TRAP”). [Invited Speaker]

5. FDA-CBER Seminar, NIH, 16 March 2000 (“Recent Progress with the Candidate Malaria Vaccine RTS,S”). [Invited Speaker]

6. Army-Navy Regional ACP-ASIM meeting. Reston VA, 16-19 November 2000 (“Update and Progress in Malaria Vaccine Development”). [Invited Speaker]

7. WRAMC Grand Rounds. Washington, DC, 9 March 2001 (“U.S. Army Progress Towards an Effective Malaria Vaccine”). [Invited Speaker]
8. Helminthological Society of Washington Quarterly Meeting. Silver Spring, MD, 14 March 2001 (“Pre-erythrocytic Malaria Vaccine Development”). [Invited Speaker]
9. Military development of sites for vaccine and drug trials. 48<sup>th</sup> Annual Meeting of the Infectious Disease Society of America, Vancouver, BC, October 21-24, 2010 [Invited Speaker].
10. The Role of the DoD in Global Health. Washington, DC, 28 July 2011 [Invited Speaker]
11. Protecting Our Volunteers and Our Nation: The Ethical Challenges of Military Research. Panel Member. PRIM&R Advancing Ethical Research Conference, National Harbor, MD December 2011 [Invited Speaker]
12. The Stimson Center and the George Washington University School of Public Health and Health Services, Panelist for the Research, Partnerships, and Field Diplomacy in Global Health Course, June 2012. [Invited Speaker]
13. Lecturer for USUHS/NMPDC Military Tropical Medicine Course: “Malaria Cases”. July 2013 [Invited Speaker]
14. Uniformed Services University, “Malaria Vaccine Development”. April 2014 [Invited Speaker]
15. 2014 International Symposium on Clinical and Translational Research; Infections and Vaccine sub-session, Shanghai, China. “Translational Research in Vaccine Development.” May 2014 [Invited Speaker]
16. Lecturer for USUHS/NMPDC Military Tropical Medicine Course: “Malaria Cases” and “Vaccine Development and Public-Private Partnerships”. July 2014 [Invited Speaker]
17. Panel member for USUHS/NMPDC Military Tropical Medicine Course: “Vaccine Development.” July 2015 [Invited Speaker]
18. 19th Annual Conference on Vaccine Research, National Foundation for Infectious Diseases: “*C. difficile* Program.” April 2016 [Invited Speaker]
19. Bio+Tech 17 Conference (Tech Council of Maryland), Rockville, MD. Panel member for “Closing the Loop on Two Critical Public Health Problems: Emerging Infections and Antibiotic Resistance.” April 2017 [Invited Speaker]

20. tecBridge NE Pennsylvania Innovation Conference, Scranton, PA. “Vaccines and Public Health.” August 2017 [Invited Speaker]